LOGIN  |  REGISTER

Merck (NYSE: MRK) Stock Quote

Last Trade: US$129.49 -1.60 -1.22
Volume: 4,624,012
5-Day Change: -1.06%
YTD Change: 18.78%
Market Cap: US$327.610B

Latest News From Merck

New Phase 3 data evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, in previously treated locally recurrent or metastatic triple-negative breast cancer First presentation of Phase 2b three-year follow-up data evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA ® (pembrolizumab) in patients with high-risk stage... Read More
RAHWAY, N.J. / May 13, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA ® ), Merck’s anti-PD-1 therapy, compared to KEYTRUDA... Read More
Approval is based on the Phase 3 KEYNOTE-966 Trial KIRKLAND, QC , May 9, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada , announced that Health Canada has granted approval of KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma... Read More
RAHWAY, N.J. / May 09, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival (DFS) for the treatment of patients with newly diagnosed,... Read More
RAHWAY, N.J. / May 08, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 1:40 p.m. PDT / 4:40 p.m. EDT. Investors, analysts, members of the media... Read More
These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication RAHWAY, N.J. / May 01, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and... Read More
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases Results build on the data supporting the clinical profile of V116 for adults RAHWAY, N.J. / Apr 29, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s... Read More
Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24% GARDASIL/GARDASIL 9 Sales Grew 14% to $2.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 17% GAAP EPS Was... Read More
Approval is based on the Phase 3 KEYNOTE-859 Trial KIRKLAND, QC , April 19, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada , announced that Health Canada has granted approval of KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or... Read More
RAHWAY, N.J. / Apr 04, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and... Read More
BASKING RIDGE, N.J. & RAHWAY, N.J. / Apr 03, 2024 / Business Wire / Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. The phase 2 portion of... Read More
RAHWAY, N.J. / Apr 01, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 25. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a... Read More
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in Europe RAHWAY, N.J. / Mar 28, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in... Read More
HealthStocksHub
WINREVAIR is a breakthrough biologic for this rare, progressive disease WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone RAHWAY, N.J. / Mar 26, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of... Read More
RAHWAY, N.J. / Mar 21, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients... Read More
Results from multiple Phase 3 trials of V116 and a real-world evidence study of pneumococcal serotypes presented at the 13 th Meeting of the International Society of Pneumonia and Pneumococcal Diseases If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults RAHWAY, N.J. / Mar 19, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today... Read More
Cutting edge & AI solution for continuous and precise monitoring of individual swine weight HOD HASHARON, Israel , March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based Artificial Intelligence ("AI") solutions for swine monitoring and production optimization, is excited to announce a strategic collaboration with MSD Animal Health, a division of Merck & Co., Inc. , Rahway, N.J. , USA (NYSE:MRK). MSD Animal Health,... Read More
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients RAHWAY, N.J. / Mar 15, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with... Read More
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers RAHWAY, N.J. / Mar 13, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV... Read More
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager RAHWAY, N.J. / Mar 11, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned... Read More
RAHWAY, N.J. / Mar 05, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 3:05 p.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to... Read More
RAHWAY, N.J. / Mar 04, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m. ET. Investors,... Read More
RAHWAY, N.J. / Feb 27, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. Investors, analysts, members of the media and the general public are invited to listen to... Read More
Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small cell lung cancer (NSCLC) based on positive overall survival results RAHWAY, N.J. / Feb 23, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines... Read More
Approval is based on the Phase 3 KEYNOTE-811 Trial KIRKLAND, QC , Feb. 12, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada , announced that Health Canada has granted approval of KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced... Read More
KIRKLAND, QC , Feb. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada , has entered into a multi-year agreement with the Vector Institute in Toronto , an independent not-for-profit corporation dedicated to advancing the field of artificial intelligence (AI) through world-class research. This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and... Read More
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries Complements Merck Animal Health’s broad portfolio of veterinary pharmaceuticals, vaccines and technology solutions RAHWAY, N.J. / Feb 05, 2024 / Business Wire / Merck Animal Health , known as MSD Animal Health outside of the United States and... Read More
Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 13% Fourth-Quarter GAAP Loss per Share Was $0.48; Non-GAAP EPS Was $0.03; GAAP Loss per Share and Non-GAAP EPS Include a Charge of $1.69 per... Read More
KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC Late-breaking OS results selected for the official Press Program at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium RAHWAY, N.J. / Jan 27, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today... Read More
KEYTRUDA doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months – in these patients AMBASSADOR (A031501)/KEYNOTE-123 is the first positive trial for KEYTRUDA as adjuvant therapy in urothelial carcinoma RAHWAY, N.J. / Jan 26, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123... Read More
RAHWAY, N.J. / Jan 23, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024. Payment will be made on April 5, 2024, to shareholders of record at the close of business on March 15, 2024. About Merck At Merck, known as MSD... Read More
RAHWAY, N.J. / Jan 19, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Feb. 1. During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2024. Investors,... Read More
More veterinary professionals are provided access to and are pursuing mental health resources for their overall wellbeing with continued improvements on the horizon RAHWAY, N.J. , Jan. 15, 2024 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the United States and Canada , a division of Merck & Co., Inc., Rahway, N.J. , USA (NYSE:MRK), today released findings of its comprehensive Veterinary Wellbeing... Read More
KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer and 39 th indication for KEYTRUDA in the US RAHWAY, N.J. / Jan 12, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved... Read More
Global Phase 3 studies started for bomedemstat (LSD1 inhibitor), nemtabrutinib (BTK inhibitor), MK-2870 (anti-TROP2 ADC) and MK-5684 (CYP11A1 inhibitor) Comprehensive clinical development programs being initiated for each investigational candidate Demonstrates company's commitment to research across novel mechanisms of action in hematologic neoplasms/malignancies, as well as lung, endometrial and prostate cancers RAHWAY,... Read More
RAHWAY, N.J. / Jan 03, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2024, at 4:30 p.m. PST /... Read More
Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with advanced EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies Application being evaluated under FDA Real-Time Oncology Review If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these... Read More
KIRKLAND, QC , and MISSISSAUGA, ON , Dec. 21, 2023 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada , and Eisai announce that KEYTRUDA ® , Merck's anti-PD-1 therapy, plus LENVIMA ® , an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, is now reimbursed with clinical criteria and conditions under the British Columbia , Alberta , Saskatchewan , Ontario , Quebec ,... Read More
RAHWAY, N.J. / Dec 20, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s New Drug Application (NDA) for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough... Read More
RAHWAY, N.J. / Dec 20, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, is scheduled to participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, Jan. 4, 2024, at 12:45 p.m. EST. Investors, analysts, members of the media and the general public are invited... Read More
Acceptance based on results from multiple Phase 3 trials If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 and older, according to CDC data from 2018-2021 RAHWAY, N.J. / Dec 19, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United... Read More
KEYTRUDA now approved for 26 indications in the EU, including seven in gastrointestinal cancers RAHWAY, N.J. / Dec 18, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers: KEYTRUDA in combination with fluoropyrimidine- and... Read More
Approval is based on results from the Phase 3 KEYNOTE-A39 trial, which demonstrated a superior overall survival benefit with KEYTRUDA plus Padcev versus platinum-based chemotherapy (gemcitabine plus cisplatin or carboplatin) in these patients Approval expands the use of KEYTRUDA plus Padcev for locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility RAHWAY, N.J. / Dec 15, 2023 / Business Wire /... Read More
First and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for these adult patients with advanced RCC This approval of WELIREG marks the first time a new treatment has been approved in a novel therapeutic class in advanced RCC since 2015 RAHWAY, N.J. / Dec 14, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug... Read More
RAHWAY, N.J. / Dec 11, 2023 / Business Wire / Merck Animal Health , known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO ® (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs. The... Read More
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157) RAHWAY, N.J. & CAMBRIDGE, Mass. / Dec 11, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase... Read More
RAHWAY, N.J., & NUTLEY, N.J. / Dec 08, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall survival (OS) and progression-free... Read More
RAHWAY, N.J. / Dec 07, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Merck is discontinuing the study based on the... Read More
First Presentation of KeyVibe-002 Results at ESMO I-O 2023 Annual Meeting RAHWAY, N.J. / Dec 07, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA ® ),... Read More
Acceptance based on results from the Phase 3 KEYNOTE-A39 trial, which showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy in these patients RAHWAY, N.J. / Nov 30, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted... Read More
Leading biopharmaceutical company taps AWS and Accenture for technology modernization LAS VEGAS / Nov 29, 2023 / Business Wire / At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com , Inc. company (NASDAQ: AMZN), today announced it is working with Accenture (NYSE: ACN) to help Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, to move a substantial portion of its IT infrastructure to AWS as part of... Read More
RAHWAY, N.J. / Nov 28, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the first quarter of 2024. Payment will be made on Jan. 8, 2024, to shareholders of record at the close of business on Dec. 15, 2023. About Merck At Merck, known as MSD outside... Read More
The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021 Results from Phase 3 trial, STRIDE-3, to be presented at World Vaccine Congress West Coast RAHWAY, N.J. / Nov 28, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from... Read More
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases RAHWAY, N.J., & CAMBRIDGE, Mass. / Nov 21, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics... Read More
RAHWAY, N.J. / Nov 20, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, Nov. 30, 2023, at 1:20 p.m. ET. Investors,... Read More
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38 th indication for KEYTRUDA in the US RAHWAY, N.J. / Nov 16, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today... Read More
Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE‑966 trial RAHWAY, N.J. / Nov 10, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with... Read More
RAHWAY, N.J. / Nov 08, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, Nov. 16, 2023, at 5:00 a.m. ET / 10:00 a.m. GMT. Investors, analysts, members of the media and the general... Read More
RAHWAY, N.J. / Nov 01, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the UBS BioPharma Conference on Wednesday. Nov. 8, 2023, at 12:00 p.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of... Read More
Approval based on results from the Phase 3 KEYNOTE-966 trial, which demonstrated significant overall survival benefit in these patients versus chemotherapy alone Approval marks sixth gastrointestinal cancer indication for KEYTRUDA-based regimens in the US RAHWAY, N.J. / Nov 01, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug... Read More
KEYTRUDA is the first therapy to show a statistically significant improvement in OS as adjuvant therapy in patients with RCC at a higher risk of recurrence following nephrectomy New OS results build on the significant disease-free survival benefit previously reported from the KEYNOTE-564 trial RAHWAY, N.J. / Nov 01, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today... Read More
Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 8% KEYTRUDA Sales Grew 17% to $6.3 Billion; Excluding the Impact of Foreign Exchange, Sales Also Grew 17% GARDASIL/GARDASIL 9 Sales Grew 13% to $2.6 Billion; Excluding the... Read More
KIRKLAND, QC , and MISSISSAUGA, ON , Oct. 25, 2023 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada , and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA®, the multiple receptor tyrosine kinase inhibitor discovered by Eisai, is reimbursed under the Alberta , British Columbia , Nova Scotia , Ontario , Quebec , and Saskatchewan drug plans with respective... Read More
KEYTRUDA plus enfortumab vedotin significantly prolonged overall survival (OS) by 53% - an improvement in median OS of more than 15 months - compared to chemotherapy in the total patient population Late-breaking results from the Phase 3 KEYNOTE-A39/EV-302 trial were selected for the official Press Briefing and presentation during a Presidential Symposium session at the European Society for Medical Oncology Congress 2023... Read More
At a pre-specified interim analysis in LITESPARK-005, WELIREG reduced the risk of disease progression or death compared to everolimus First Phase 3 trial to show positive results in patients with advanced RCC following both immune checkpoint and anti-angiogenic therapies in later lines of treatment RAHWAY, N.J. / Oct 21, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today... Read More
KEYTRUDA plus concurrent chemoradiotherapy reduced the risk of disease progression or death by 30% compared to concurrent chemoradiotherapy alone KEYNOTE-A18 is the first Phase 3 study in which an immunotherapy regimen has demonstrated a significant PFS improvement in locally advanced cervical cancer compared to concurrent chemoradiotherapy alone RAHWAY, N.J. / Oct 20, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD... Read More
In the KEYNOTE-811 trial, the KEYTRUDA regimen demonstrated a statistically significant PFS improvement in advanced HER2-positive gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (Combined Positive Score [CPS] ≥1) compared to trastuzumab and chemotherapy alone RAHWAY, N.J. / Oct 20, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3... Read More
KEYTRUDA plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy (24.3% vs. 15.6%, respectively) KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient population RAHWAY, N.J. / Oct 20, 2023 / Business Wire / Merck (NYSE: MRK), known... Read More
This regimen with KEYTRUDA is the first and only anti-PD-1/L1 therapy in resectable NSCLC to demonstrate a statistically significant improvement in overall survival versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo alone, regardless of PD-L1 expression KEYTRUDA-based regimen also improved event-free survival, the trial’s other dual primary endpoint (median EFS by nearly 2.5 years, 47.2 months for the... Read More
Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the reach of ADCs for patients across multiple types of cancer Daiichi Sankyo and Merck to co-develop and co-commercialize patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan worldwide except for Japan where Daiichi Sankyo... Read More
RAHWAY, N.J. / Oct 17, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of PREVYMIS ® (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient... Read More
Approval marks the sixth NSCLC indication for KEYTRUDA and builds upon Merck’s progress in earlier stages of certain cancers across our oncology portfolio RAHWAY, N.J., October 16, 2023--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of patients with... Read More
Decision marks fifth approval for KEYTRUDA in lung cancer in the EU RAHWAY, N.J. / Oct 16, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC) who are at high risk of recurrence following... Read More
Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE-859 trial If approved, a KEYTRUDA combination would become an option in the EU for the treatment of both HER2-negative and HER2-positive advanced gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (CPS ≥1) RAHWAY, N.J. / Oct 13, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today... Read More
First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for ESMO Presidential Symposium Session and official Press Briefings Key data to be presented for KEYTRUDA ® (pembrolizumab) in earlier stages of cancer across multiple tumor types, including presentation of overall survival results... Read More
KEYTRUDA ® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC RAHWAY, N.J. / Oct 10, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a... Read More
KEYTRUDA significantly improved DFS as adjuvant therapy versus observation for patients with localized MIUC and locally advanced urothelial carcinoma First positive study for KEYTRUDA as adjuvant therapy for these patients RAHWAY, N.J. / Oct 05, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating... Read More
RAHWAY, N.J. / Oct 05, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 26. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a... Read More
Application based on clinically meaningful results from the Phase 3 STELLAR trial If approved, sotatercept would be the first in its class, bringing a novel approach to address a rare and progressive disease of the pulmonary arteries RAHWAY, N.J. / Sep 28, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has... Read More
RAHWAY, N.J. & NUTLEY, N.J. / Sep 22, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung... Read More
First Phase 3 results for the KEYTRUDA ® (pembrolizumab) and Padcev ® (enfortumab vedotin-ejfv) combination showed a statistically significant and clinically meaningful improvement in OS, PFS and key secondary endpoint of overall response rate versus chemotherapy in these patients, who may or may not be eligible for cisplatin-based chemotherapy RAHWAY, N.J. / Sep 22, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD... Read More
Acceptance based on results from the Phase 3 KEYNOTE-A18 trial, which showed a statistically significant and clinically meaningful improvement in progression-free survival in these patients RAHWAY, N.J. / Sep 20, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental... Read More
Acceptance based on results from the Phase 3 LITESPARK-005 trial, which showed a statistically significant and clinically meaningful improvement in progression-free survival compared to everolimus in patients with advanced RCC that progressed following PD-1/L1 and VEGF-TKI therapies If approved, WELIREG would provide a new, novel mechanism of action for patients with advanced RCC in need of new options RAHWAY, N.J. / Sep 19,... Read More
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial RAHWAY, N.J. / Sep 15, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, for the... Read More
Exploratory post-hoc analysis of STELLAR shows potential of sotatercept to improve cardiovascular function Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date; safety profile of sotatercept consistent with previous studies and efficacy improvements maintained after one year of therapy Nine Merck-sponsored abstracts in PAH featured at European... Read More
Milestone signifies ongoing effort to help prepare for outbreaks of Zaire ebolavirus RAHWAY, N.J. / Sep 07, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire... Read More
Data showed no cases of certain HPV-related high-grade disease, certain studied cancers or genital warts through 10 years for boys and girls vaccinated at ages 9-15 years RAHWAY, N.J. / Sep 05, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics, for girls and boys who received... Read More
RAHWAY, N.J. / Sep 05, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday,... Read More
Approval based on progression-free survival benefit demonstrated in Phase 3 KEYNOTE-811 trial KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population RAHWAY, N.J. / Aug 29, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in... Read More
RAHWAY, N.J. / Aug 29, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie C. Green, senior vice president and head of late-stage oncology, Global Clinical Development, is scheduled to participate in a fireside chat at the Citi 18th Annual BioPharma Conference on Wednesday, Sept. 6, 2023, at 1:50 p.m. EDT. Investors, analysts, members of the media... Read More
Program plans to enroll approximately 17,000 participants across three global studies RAHWAY, N.J. / Aug 25, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for the treatment... Read More
RAHWAY, N.J. & NUTLEY, N.J. / Aug 25, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients with recurrent or metastatic head... Read More
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent RAHWAY, N.J. / Aug 24, 2023 / Business Wire / AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved in Japan for the treatment of adult patients... Read More
First positive Phase 3 results for WELIREG from LITESPARK-005 showed statistically significant improvements in PFS versus everolimus in these patients RAHWAY, N.J. / Aug 18, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha... Read More
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease RAHWAY, N.J. / Aug 03, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months... Read More
Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% KEYTRUDA Sales Grew 19% to $6.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% GARDASIL/GARDASIL 9 Sales Grew 47% to $2.5 Billion;... Read More
KEYTRUDA ® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient population RAHWAY, N.J. / Jul 28, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside... Read More
Topline results demonstrated V116 elicited positive immune responses in both vaccine-naïve and vaccine-experienced adult patient populations The 21 serotypes covered by V116 are responsible for 85% of invasive pneumococcal disease in individuals 65 and older RAHWAY, N.J. / Jul 27, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from two... Read More
V940-001 is the first Phase 3 study of a planned comprehensive clinical development program being initiated following the positive primary analysis of the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial reported at AACR and ASCO earlier this year RAHWAY, N.J. & CAMBRIDGE, Mass. / Jul 26, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology... Read More
RAHWAY, N.J. / Jul 25, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share of the company’s common stock for the fourth quarter of 2023. Payment will be made on Oct. 6, 2023, to shareholders of record at the close of business on Sept. 15, 2023. About Merck At Merck, known as MSD outside... Read More
Surmodics

COPYRIGHT ©2023 HEALTH STOCKS HUB